Anne Chiang, MD, PhD
Biography
Anne Chiang, MD, PhD, is a thoracic medical oncologist who cares for patients with lung cancer, including non-small cell lung cancer—the most common kind—and small cell lung cancer. She has concentrated on building a small cell lung cancer program with a comprehensive portfolio of clinical trials testing novel therapeutics for these patients. In addition, she is active as a lung cancer investigator, running a national cooperative group trial for over 800 patients to understand the best frontline therapy for non-small cell lung cancer patients who are PDL1 marker positive.
Researchers are continually investigating new approaches and treatments for all types of cancer, Dr. Chiang says. “I am so optimistic and excited about the impact of clinical research and advances in the field that are helping patients to live longer and better lives, even with a diagnosis of lung cancer,” she says. Her own research background includes translational studies of metastasis, and the development of clinical trials and translational studies to test novel agents and combinations with immune checkpoint inhibitors for both small cell and non-small cell lung tumors. “I am dedicated to quality improvement for patient-centered cancer services and champion the use of patient-reported outcomes,” she says.
Dr. Chiang recently received the American Society of Clinical Oncology 2020 Joseph V. Simone Award and Lecture for excellence in Quality and Safety in the Care of Patients with Cancer. This award was created in honor of Joseph V. Simone, MD, to recognize an extraordinary individual who has made significant contributions to the quality and safety of cancer care. The recipient is an innovator and leader with proven ability to bring projects from conception to broad implementation.
“Listening to and guiding patients when they are diagnosed with cancer is so important,” says Dr. Chiang. “This is a particularly vulnerable time for patients and their families. Good communication can make such a difference on the impact of the diagnosis as well as on the treatment experience.” When seeing a new patient, she often says, “You are in the right place. Our team is here to support you and your family however we can, and to always go the extra mile.”
Titles
- Associate Professor
- Associate Cancer Center Director, Clinical Initiatives
Education & Training
- FellowMemorial Sloan Kettering Cancer Center (2006)
- Senior ResidentNew York Presbyterian Hospital - Columbia Medical Center (2003)
- InternNew York Presbyterian Hospital Columbia Medical Center (2000)
- MDCornell University Medical College (1999)
- PhDHarvard University (1995)
- ABPrinceton University, Molecular Biology (1987)
Languages Spoken
- English
- Deutsch (German)
Additional Information
- CDA Award (2007-2010): ASCO (2007)
- YIA Recipient: ASCO (2005)
- Clinical Scholars Award (2005-2007): Charles Dana Foundation (2005)
- Cancer Chemotherapy Training Program Grantee (2004-2005): National Institute of Health (NIH) (2004)
- Fulbright Fellowship: (1987)
- American Association for Cancer Research (2004 - 2005): Member
- American Society of Hematology (2003 - 2004): Member
- American Society of Clinical Oncology (2003 - Present): Member
- Matteson K, Nassar A, Ellis-Caleo T, Mingo E, Aggarwal V, Sridhar A, Alam S, Crowley F, Aboubakar Nana F, Ahmed M, Grohe C, Zurera Berjaga M, Pinato D, Watson A, Chiang A, Naqash A. Comparison of chemotherapy to chemo-immunotherapy as first-line treatment in patients with advanced large cell neuroendocrine carcinomas (LCNECs) of mixed histology: A multi-institutional international retrospective study. Journal Of Clinical Oncology 2024, 42: 8602-8602. DOI: 10.1200/jco.2024.42.16_suppl.8602.
- Nassar A, Matteson K, Ardeshir F, Gray J, Baena Espinar J, Kwiatkowski D, Aboubakar Nana F, Grohe C, Citarella F, Pancirer D, Cheung J, Watson A, Sridhar A, Crowley F, Kaldas D, Kim C, Sankar K, Awosika N, Naqash A, Chiang A. Exploring systemic treatment approaches for advanced pure large cell neuroendocrine carcinoma (LCNEC): A multicenter retrospective analysis. Journal Of Clinical Oncology 2024, 42: 8106-8106. DOI: 10.1200/jco.2024.42.16_suppl.8106.
- Hummel H, Paz-Ares L, Blackhall F, Chiang A, Dowlati A, Goldman J, Izumi H, Mok T, Sands J, Martinez P, Anderson E, Bharania P, Yu B, Yu Y, Pulla M. 214TiP Tarlatamab after chemoradiotherapy in limited-stage small cell lung cancer (LS-SCLC): DeLLphi-306 (NCT06117774). ESMO Open 2024, 9: 102787. DOI: 10.1016/j.esmoop.2024.102787.
- Jairam V, Soulos P, Madhav K, Gross C, Slotman B, Chiang A, Park H. Differential Effect of Consolidative Thoracic Radiation Therapy in Extensive-Stage Small Cell Lung Cancer Based on Sex. Advances In Radiation Oncology 2023, 9: 101413. PMID: 38778819, PMCID: PMC11110031, DOI: 10.1016/j.adro.2023.101413.
- Gettinger S, Goldberg S, Chiang A, Wilson F, Kim S, Rowen E, Gerrish H, Duffield E, Davies M, Dest V, Jackson R, Pope J, Myint H, Langermann S, Cheng W, Rimm D, Chen L, Herbst R. MA15.07 NC318, an Anti-Siglec-15 Humanized mAb, Alone and in Combination with Pembrolizumab in Immunotherapy Pretreated NSCLC. Journal Of Thoracic Oncology 2023, 18: s155. DOI: 10.1016/j.jtho.2023.09.224.
- Li Y, Yang S, Chiang A, Gross C, Wang S. Using real world practice patterns to identify clinical equipoise in cancer treatment: Advanced non-small cell lung cancer as an exemplar. JCO Oncology Practice 2023, 19: 539-539. DOI: 10.1200/op.2023.19.11_suppl.539.
- Tan J, Yang S, Dinan M, Chiang A, Gross C, Wang S. Mutation-specific costs of advanced non-small cell lung cancer treatment. JCO Oncology Practice 2023, 19: 14-14. DOI: 10.1200/op.2023.19.11_suppl.14.
- Mack P, Redman M, Kozono D, Callis S, Tukachinsky H, Tolba K, Neal J, Waqar S, Dragnev K, Aggarwal C, Hirsch F, Patel J, Herbst R, Chiang A, Reckamp K, Kelly K, Borghaei H, Gray J, Gandara D. The effect of ctDNA tumor fraction (TF) on overall survival and concordance between tissue genomics and ctDNA in Lung-MAP. Journal Of Clinical Oncology 2023, 41: 9035-9035. DOI: 10.1200/jco.2023.41.16_suppl.9035.
- Carbone D, Waqar S, Chaft J, Kris M, Johnson B, Lee J, Wistuba I, Kwiatkowski D, Bunn P, Schulze K, Johnson A, Brandao E, Awad M, Reckamp K, Chiang A, Nicholas A, Rusch V. Abstract CT215: Efficacy and safety of adjuvant (adj) atezolizumab (atezo) from the Phase 2 LCMC3 study. Cancer Research 2023, 83: ct215-ct215. DOI: 10.1158/1538-7445.am2023-ct215.
- Carbone D, Waqar S, Chaft J, Kris M, Johnson B, Lee J, Wistuba I, Kwiatkowski D, Bunn P, Schulze K, Johnson A, Brandao E, Awad M, Reckamp K, Chiang A, Nicholas A, Rusch V. 145MO Updated survival, efficacy and safety of adjuvant (adj) atezolizumab (atezo) after neoadjuvant (neoadj) atezo in the phase II LCMC3 study. Journal Of Thoracic Oncology 2023, 18: s90-s91. DOI: 10.1016/s1556-0864(23)00339-8.
- Power S, Bickel K, Chen R, Chiang A, Garrett-Mayer L, Makhoul I, Mougalian S, Shapiro C, Siegel R, Smith C, Rocque G, Kozlik M, Crist S, Kamal A. Associations of Early Completion of Advance Directives With Key End-of-Life Quality Measures: Analysis of an ASCO Quality Oncology Practice Initiative Patient Cohort. JCO Oncology Practice 2023, 19: e520-e526. PMID: 36669136, DOI: 10.1200/op.22.00464.
- Blinder VS, Garrett-Mayer E, Jacobsen PB, Kozlik MM, Markham MJ, Siegel RD, Kamal AH, Crist STS, Rosenthal J, Chiang AC, _ _. Oral Chemotherapy Metric Performance in Quality Oncology Practice Initiative Practices: Updated Trends and Analysis. Journal Of The National Comprehensive Cancer Network 2022, 20: 1099-1106.e2. PMID: 36240846, DOI: 10.6004/jnccn.2022.7024.
- Chiang A, Kaur M, Assaf Z, Fine A, Zhao Y, Cao Y, Madison R, Oxnard G, Tolba K, Zuniga R, Lakhanpal S, Antic V, Bourla A, Schulze K. EP16.02-002 Circulating Tumor DNA (ctDNA) Changes in Patients With Lung Cancer from a Real-World Prospective Clinico-Genomic (PCG) Study. Journal Of Thoracic Oncology 2022, 17: s571-s572. DOI: 10.1016/j.jtho.2022.07.1033.
- Sands J, Reck M, Navarro A, Chiang A, Lu S, Peled N, Paz-Ares L, Kerr S, Takahashi T, Smolin A, Chen X, Zhao B, El-Osta H, Califano R. KeyVibe-008: Randomized, phase 3 study of first-line vibostolimab plus pembrolizumab plus etoposide/platinum versus atezolizumab plus EP in extensive-stage small cell lung cancer. Journal Of Clinical Oncology 2022, 40: tps8606-tps8606. DOI: 10.1200/jco.2022.40.16_suppl.tps8606.
- Hammon D, Souza E, Chiang A, Shulman L, Kubal T. Plenary Session—The Patient Journey: Access to Cancer Care. Journal Of The National Comprehensive Cancer Network 2022, 20: 1-4. DOI: 10.6004/jnccn.2022.5011.
- Makhoul I, Anders M, Siegel R, Chiang A, Markham MJ, Chen RC, Mougalian S, Arnaoutakis K, Giuliani M, Im A, Kozlik MMP, Crist STS, Garrett-Mayer E, Kamal A. Hematology/Oncology Fellowship Programs' Participation in the Quality Oncology Practice Initiative. JCO Oncology Practice 2022, 18: e1209-e1218. PMID: 35467961, DOI: 10.1200/op.21.00807.
- Siegel RD, Garrett-Mayer E, Lipner RS, Kozlik MMP, Vandergrift JL, Crist STS, Chen RC, Chiang AC, Kamal AH, Force O. Relationship Between Participation in ASCO's Quality Oncology Practice Initiative Program and American Board of Internal Medicine's Maintenance of Certification Program. JCO Oncology Practice 2022, 18: e1350-e1356. PMID: 35363501, DOI: 10.1200/op.21.00777.
- Chen RC, Garrett-Mayer E, Kamal AH, Makhoul I, Kozlik MMP, Crist STS, Chiang AC, Force O. Pre-Treatment Staging Imaging in Rectal Cancer: Results From the Quality Oncology Practice Initiative. JCO Oncology Practice 2022, 18: e1367-e1373. PMID: 35353546, DOI: 10.1200/op.21.00455.
- Sugalski JM, Franco T, Shulman LN, Souza E, Hochberg E, Chiang A, Lawrence S, Krause D, Kubal T. COVID-19 and Cancer Center Operations: Lessons Learned From the NCCN Best Practices Committee. Journal Of The National Comprehensive Cancer Network 2022, 20: 1-4. PMID: 34991065, DOI: 10.6004/jnccn.2021.7102.
- Ganti AKP, Loo BW, Bassetti M, Blakely C, Chiang A, D'Amico TA, D'Avella C, Dowlati A, Downey RJ, Edelman M, Florsheim C, Gold KA, Goldman JW, Grecula JC, Hann C, Iams W, Iyengar P, Kelly K, Khalil M, Koczywas M, Merritt RE, Mohindra N, Molina J, Moran C, Pokharel S, Puri S, Qin A, Rusthoven C, Sands J, Santana-Davila R, Shafique M, Waqar SN, Gregory KM, Hughes M. Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. Journal Of The National Comprehensive Cancer Network : JNCCN 2021, 19: 1441-1464. PMID: 34902832, DOI: 10.6004/jnccn.2021.0058.
- Mbewe A, Pike P, Lewis R, Kortmansky J, Chiang A, Kanowitz J. Implementing the cancer and aging research group (CARG) tool in the ambulatory oncology setting to drive informed treatment selection. Journal Of Clinical Oncology 2021, 39: 209-209. DOI: 10.1200/jco.2020.39.28_suppl.209.
- Newton B, Chiang A. Therapeutic Advances in Small Cell Lung Cancer Management. Current Cancer Research 2021, 175-195. DOI: 10.1007/978-3-030-74028-3_8.
- “The waiting is the worst”: Development of a next day access (NDA) program for patients with cancer.Mougalian S, Shomsky L, Campos M, Chiang A. “The waiting is the worst”: Development of a next day access (NDA) program for patients with cancer. Journal Of Clinical Oncology 2021, 39: 205-205. DOI: 10.1200/jco.2020.39.28_suppl.205.
- Owonikoko T, Boyer M, Johnson M, Govindan R, Rodrigues L, Blackhall F, Boosman R, Champiat S, Hummel H, Lai W, Udagawa H, Chiang A, Dowlati A, Hann C, Salgia R, Vokes E, Minocha M, Sadraei N, Shetty A, Smit M, Zhang Y, Sable B, Pati A, Roy S, Borghaei H. OA11.03 A Phase 1 Study of AMG 757, Half-Life Extended Bispecific T-Cell Engager (BiTE®)Immune Therapy Against DLL3, in SCLC. Journal Of Thoracic Oncology 2021, 16: s126. DOI: 10.1016/j.jtho.2021.01.313.
- Walia G, Lu M, Bourla A, Santos E, Schulze K, Cabili M, Williams E, Mirkovic N, Dicecca R, Lee S, Fang B, Schwartzberg L, Herbst R, Chiang A. P09.55 A Platform to Prospectively Link Real-World Clinico-Genomic, Imaging, and Outcomes Data for Patients With Lung Cancer. Journal Of Thoracic Oncology 2021, 16: s316-s317. DOI: 10.1016/j.jtho.2021.01.483.
- Borghaei H, Boyer M, Johnson M, Govindan R, Rodrigues L, Blackhall F, Boosman R, Champiat S, Hummel H, Lai W, Udagawa H, Chiang A, Dowlati A, Hann C, Salgia R, Vokes E, Minocha M, Hashemi-Sadraei N, Shetty A, Smit M, Yang H, Owonikoko T. 359 AMG 757, a half-life extended bispecific T-cell engager (BiTE®) immune therapy against DLL3 in SCLC: phase 1 interim results. Journal For ImmunoTherapy Of Cancer 2020, 8: a384-a384. DOI: 10.1136/jitc-2020-sitc2020.0359.
- Yang D, Park H, Jairam V, Decker R, Chiang A, Gross C, Yu J. Association Between Prophylactic Cranial Irradiation and Improved Overall Survival in Small Cell Lung Cancer. International Journal Of Radiation Oncology • Biology • Physics 2020, 108: e106. DOI: 10.1016/j.ijrobp.2020.07.1223.
- Owonikoko T, Borghaei H, Champiat S, Paz-Ares L, Govindan R, Boyer M, Johnson M, Udagawa H, Hummel H, Salgia R, Blackhall F, Boosman R, Lai W, Dowlati A, Vokes E, Hann C, Chiang A, Endraca M, Soman N, Smit M. Phase I study of AMG 757, a half-life extended bispecific T-cell engager (HLE BiTE immune therapy) targeting DLL3, in patients with small cell lung cancer (SCLC). Journal Of Clinical Oncology 2020, 38: tps9080-tps9080. DOI: 10.1200/jco.2020.38.15_suppl.tps9080.
- Lu M, Walia G, Schulze K, Doral M, Maund S, Gaffey S, Cabili M, Bourla A, Green R, Santos E, Herbst R, Chiang A, Schwartzberg L. A multi-stakeholder platform to prospectively link longitudinal real-world clinico-genomic, imaging, and outcomes data for patients with metastatic lung cancer. Journal Of Clinical Oncology 2020, 38: tps2087-tps2087. DOI: 10.1200/jco.2020.38.15_suppl.tps2087.
- Yang D, Jairam V, Park H, Decker R, Chiang A, Gross C, Yu J. Use of prophylactic cranial irradiation in patients with extensive-stage small cell lung cancer receiving immunotherapy. Journal Of Clinical Oncology 2020, 38: e19309-e19309. DOI: 10.1200/jco.2020.38.15_suppl.e19309.
- Urick B, Stover A, Deal A, Jansen J, Chiang A, Cleeland C, Zylla D, Basch E. Development and evaluation of patient reported outcomes-based performance measures during chemotherapy. Journal Of Clinical Oncology 2020, 38: e19175-e19175. DOI: 10.1200/jco.2020.38.15_suppl.e19175.
- Stover A, Urick B, Deal A, Jansen J, Henson S, Miller R, Smith T, Scholle S, Chiang A, Cleeland C, Deutsch Y, Zylla D, Pitzen C, Snyder C, McNiff K, Krzyzanowska M, Spears P, Smith M, Geoghegan C, Basch E. ON5 DEVELOPMENT AND TESTING OF PATIENT-REPORTED OUTCOME PERFORMANCE MEASURES (PRO-PMS) FOR COMPARING ONCOLOGY PRACTICES. Value In Health 2019, 22: s413. DOI: 10.1016/j.jval.2019.09.085.
- Keng M, Cunningham G, Gilmore T, Gilligan T, Quinn D, Kaufman L, Bingham J, Guerrier V, Chiang A, Mohamed A, Hagemann J. ASCO Quality Training Program: Five-year review. Journal Of Clinical Oncology 2019, 37: 7-7. DOI: 10.1200/jco.2019.37.27_suppl.7.
- Stover A, Urick B, Deal A, Jansen J, Henson S, Miller R, Smith T, Scholle S, Chiang A, Cleeland C, Deutsch Y, Zylla D, Pitzen C, Snyder C, McNiff K, Krzyzanowska M, Spears P, Smith M, Geoghegan C, Basch E. Development and testing of patient-reported outcome performance measures (PRO-PMs) for oncology practice. Journal Of Clinical Oncology 2019, 37: 173-173. DOI: 10.1200/jco.2019.37.27_suppl.173.
- Dendy Case M, Uhlig J, Blasberg J, Boffa D, Chiang A, Gettinger S, Kim H. Benefit of combining local treatment and systemic therapy for stage IV NSCLC: Results from the National Cancer Database. Journal Of Clinical Oncology 2019, 37: 8545-8545. DOI: 10.1200/jco.2019.37.15_suppl.8545.
- Uhlig J, Dendy M, Goldberg S, Chiang A, Blasberg J, Kim H. 03:00 PM Abstract No. 278 Thermal ablation versus stereotactic radiation therapy for stage 4 lung cancer: contemporary trends and outcomes from the National Cancer Database. Journal Of Vascular And Interventional Radiology 2019, 30: s124-s125. DOI: 10.1016/j.jvir.2018.12.342.
- Kidwai W, Engelking C, Pyle J, Chiang A. Standardizing goals of care (GoC) documentation for new patients with metastatic disease. Journal Of Clinical Oncology 2018, 36: 26-26. DOI: 10.1200/jco.2018.36.34_suppl.26.
- Campbell A, Herbst R, Gettinger S, Goldberg S, Kluger H, Chiang A, Lilenbaum R, Schalper K, Sowell R, Kaech S, Decker R. Final Results of a Phase I Prospective Trial Evaluating the Combination of Stereotactic Body Radiation Therapy (SBRT) with Concurrent Pembrolizumab in Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) or Melanoma. International Journal Of Radiation Oncology • Biology • Physics 2018, 102: s18-s19. DOI: 10.1016/j.ijrobp.2018.06.134.
- Improved acute pain management in oncology patients using early scheduled contact with a pain coach.LaSala J, Chiang A, Severino K. Improved acute pain management in oncology patients using early scheduled contact with a pain coach. Journal Of Clinical Oncology 2018, 36: 293-293. DOI: 10.1200/jco.2018.36.30_suppl.293.
- Chiang A, Adelson K, Kapo J, Severino K, Lilenbaum R. Simple interventions to decrease use of chemotherapy in patients at the end of life. Journal Of Clinical Oncology 2018, 36: 181-181. DOI: 10.1200/jco.2018.36.30_suppl.181.
- Chiang A, Fernandes A, Pavilack M, Wu J, Laliberté F, Duh M, Chehab N, Subramanian J. MA15.11 Real World Biomarker Testing and Treatment Patterns in Patients with Advanced NSCLC Receiving EGFR-TKIs. Journal Of Thoracic Oncology 2018, 13: s410-s411. DOI: 10.1016/j.jtho.2018.08.447.
- Campbell A, Herbst R, Gettinger S, Goldberg S, Kluger H, Chiang A, Lilenbaum R, Schalper K, Sowell R, Kaech S, Decker R. Final results of a phase I prospective trial evaluating the combination of stereotactic body radiotherapy (SBRT) with concurrent pembrolizumab in patients with metastatic non-small cell lung cancer (NSCLC) or melanoma. Journal Of Clinical Oncology 2018, 36: 9099-9099. DOI: 10.1200/jco.2018.36.15_suppl.9099.
- Goldberg S, Gettinger S, Mahajan A, Herbst R, Chiang A, Lilenbaum R, Jilaveanu L, Rowen E, Gerrish H, Komlo A, Wei W, Chiang V, Kluger H. Durability of brain metastasis response and overall survival in patients with non-small cell lung cancer (NSCLC) treated with pembrolizumab. Journal Of Clinical Oncology 2018, 36: 2009-2009. DOI: 10.1200/jco.2018.36.15_suppl.2009.
- Talsania A, Chiang A. Chapter 7 A Practical Approach to Management of Small Cell Lung Cancer. 2018, 117-129. DOI: 10.1016/b978-0-323-48565-4.00007-2.
- Daniel D, Rudin C, Hart L, Spigel D, Edelman M, Goldschmidt J, Bordoni R, Glisson B, Burns T, Dowlati A, Dy G, Beck T, Jotte R, Liu S, Kapoun A, Faoro L, Chiang A. 1530PD Results of a randomized, placebo-controlled, phase 2 study of tarextumab (TRXT, anti-Notch2/3) in combination with etoposide and platinum (EP) in patients (pts) with untreated extensive-stage small-cell lung cancer (ED-SCLC). Annals Of Oncology 2017, 28: v540. DOI: 10.1093/annonc/mdx386.004.
- Zhang C, Graf R, Jendrisak A, Anderson A, Ontiveros P, Orr S, Chiang A, Spigel D, Rudin C, Holmgren E, Dupont J, Argast G, Faoro L, Zhou L, Lewicki J, Kapoun A. Abstract 1727: Circulating Tumor Cells (CTCs) in patients with extensive stage small cell lung cancer and their association with clinical outcome. Cancer Research 2017, 77: 1727-1727. DOI: 10.1158/1538-7445.am2017-1727.
- O'Connor J, Seidl-Rathkopf K, You P, Nussbaum N, Torres A, Fessele K, Darius K, Adelson K, Yin E, Presley C, Chiang A, Ross J, Abernethy A, Gross C. Adoption of immunotherapy into real-world practice: Insights from the use of checkpoint inhibitors. Journal Of Clinical Oncology 2017, 35: e14583-e14583. DOI: 10.1200/jco.2017.35.15_suppl.e14583.
- Presley C, Soulos P, Chiang A, Longtine J, Adelson K, Herbst R, Nussbaum N, Sorg R, Abernethy A, Agarwala V, Gross C. Disparities in next generation sequencing in a population-based community cohort of patients with advanced non-small cell lung cancer. Journal Of Clinical Oncology 2017, 35: 6563-6563. DOI: 10.1200/jco.2017.35.15_suppl.6563.
- O'Connor J, Seidl-Rathkopf K, Torres A, You P, Nussbaum N, Fessele K, Darius K, Adelson K, Yin E, Presley C, Chiang A, Ross J, Abernethy A, Gross C. Racial disparities in the use of programmed death-1 checkpoint inhibitors. Journal Of Clinical Oncology 2017, 35: 3068-3068. DOI: 10.1200/jco.2017.35.15_suppl.3068.
- Adelson K, Stutsky M, Fradkin M, Harrison M, Abdelghany O, Morrow B, Smith M, Havriliak R, Kregling S, Lyons C, Chiang A, Cohen H. Should Cancer Centers start their own specialty pharmacy? Quality and economic data from the oral chemotherapy program at Smilow Cancer Hospital and Yale New Haven Health System. Journal Of Clinical Oncology 2017, 35: 108-108. DOI: 10.1200/jco.2017.35.8_suppl.108.
- Chiang A, Reeder-Hayes K, McNiff K, Evans T, Lennes I, Eaton E, Kamal A. Challenges, barriers, and keys to success for sustainable quality improvement in oncology: A focus group of oncology quality leaders. Journal Of Clinical Oncology 2017, 35: 78-78. DOI: 10.1200/jco.2017.35.8_suppl.78.
- Chiang A, Barysauskas C, Conti-Kalchik T, Gilmore T, Hendricks C, Neuss M, Jacobson J. Comparison of initial and recertification QOPI scores: Maintaining compliance through direct surveyor and practice interaction. Journal Of Clinical Oncology 2017, 35: 246-246. DOI: 10.1200/jco.2017.35.8_suppl.246.
- Barbarotta L, Jauk M, Chiang A, Sanft T. Hard-wiring survivorship care plan delivery. Journal Of Clinical Oncology 2017, 35: 113-113. DOI: 10.1200/jco.2017.35.8_suppl.113.
- Lu C, Morgensztern D, Chiang A, Onn A, Sepesi B, Vaporciyan A, Chang J, Komaki R, Wistuba I, Herbst R. Cancer of the Lung. 2017, 1-30. DOI: 10.1002/9781119000822.hfcm085.
- Chiang A, Ellis P, Zon R. Perspectives on the Use of Clinical Pathways in Oncology Care. American Society Of Clinical Oncology Educational Book 2017, 37: 155-159. DOI: 10.14694/edbk_175533.
- Decker R, Goldberg S, Nath S, Husain Z, Lilenbaum R, Schalper K, Chiang A, Altan M, Zelterman D, Kaech S, Herbst R, Gettinger S. P3.02c-048 A Phase I/II Trial Evaluating the Combination of Stereotactic Body Radiotherapy and Pembrolizumab in Metastatic NSCLC Topic: IT. Journal Of Thoracic Oncology 2017, 12: s1303-s1304. DOI: 10.1016/j.jtho.2016.11.1843.
- Sequist L, Chiang A, Gilbert J, Gordon M, Conkling P, Thompson D, Marcoux J, Antonia S, Liu B, Shames D, Lopez-Chavez A, O'Hear C, Fasso M, Gettinger S. 1425PD Clinical activity, safety and predictive biomarkers results from a phase Ia atezolizumab (atezo) trial in extensive-stage small cell lung cancer (ES-SCLC). Annals Of Oncology 2016, 27: vi493. DOI: 10.1093/annonc/mdw389.03.
- Badin F, Chiang A, Fisher W, Orlov S, Harper H, Eskander E, Harb W, Kio E, Gopalan P, Haggstrom D, Burdaeva O, Zahlten-Kumeli A, Aggarwal S, Obreja M, Gorbunova V. Carfilzomib (CFZ), carboplatin and etoposide for previously untreated extensive-stage small cell lung cancer (ES-SCLC): Phase 1b results from a phase 1b/2 study. Journal Of Clinical Oncology 2016, 34: e20092-e20092. DOI: 10.1200/jco.2016.34.15_suppl.e20092.
- Xia B, Wurtz A, Gettinger S, Herbst R, Chiang A, Wan M, Sklar J, Neumeister V, Politi K, Goldberg S. HER2 amplification in EGFR mutant NSCLC after acquired resistance (AR) to EGFR-directed therapies. Journal Of Clinical Oncology 2016, 34: 9049-9049. DOI: 10.1200/jco.2016.34.15_suppl.9049.
- Schalper K, Carvajal-Hausdorf D, McLaughlin J, Altan M, Chiang A, Velcheti V, Kaftan E, Zhang J, Lu L, Rimm D, Han B, Lu H, Zhao H, Herbst R. Objective measurement and significance of PD-L1, B7-H3, B7-H4 and TILs in small cell lung cancer (SCLC). Journal Of Clinical Oncology 2016, 34: 8566-8566. DOI: 10.1200/jco.2016.34.15_suppl.8566.
- Chiang A, Rudin C, Spira A, Jotte R, Gadgeel S, Mita A, Hart L, Gluck W, Liu S, Kapoun A, Xu L, Hill D, Zhou L, Dupont J, Spigel D. Updated results of phase 1b study of tarextumab (TRXT, anti-Notch2/3) in combination with etoposide and platinum (EP) in patients (pts) with untreated extensive-stage small-cell lung cancer (ED-SCLC). Journal Of Clinical Oncology 2016, 34: 8564-8564. DOI: 10.1200/jco.2016.34.15_suppl.8564.
- Gettinger S, Zhang X, Homer R, Possick J, Wurtz A, Goldberg S, Chiang A, Herbst R, Rubinowitz A. Pneumonitis in non-small cell lung cancer (NSCLC) patients treated with programmed death 1 (PD1) axis inhibitors. Journal Of Clinical Oncology 2016, 34: 9030-9030. DOI: 10.1200/jco.2016.34.15_suppl.9030.
- Stover A, Chiang A, Basch E. ASCO PRO workgroup update: Patient-reported outcome measures as a quality indicator. Journal Of Clinical Oncology 2016, 34: 276-276. DOI: 10.1200/jco.2016.34.7_suppl.276.
- Amport S, Adelson K, Fradkin M, Havriliak R, Harrison M, Abdelghany O, Kregling S, Wright J, Morrow B, Sterling R, Smith M, Esposito F, Stutsky M, Miller L, Lilenbaum R, Lyons C, Chiang A, Cohen H. Multidisciplinary process improvement to optimize oral chemotherapy safety. Journal Of Clinical Oncology 2016, 34: 134-134. DOI: 10.1200/jco.2016.34.7_suppl.134.
- Chiang A. Why the Quality Oncology Practice Initiative Matters: It’s Not Just About Cost. American Society Of Clinical Oncology Educational Book 2016, 36: e102-e107. DOI: 10.14694/edbk_160113.
- Goldberg S, Gettinger S, Mahajan A, Herbst R, Chiang A, Tsiouris A, Vortmeyer A, Jilaveanu L, Speaker S, Madura M, Rowen E, Gerrish H, Knapp-Perry E, Yao X, Chiang V, Kluger H. Activity and safety of pembrolizumab in patients with metastatic non-small cell lung cancer with untreated brain metastases. Journal Of Clinical Oncology 2015, 33: 8035-8035. DOI: 10.1200/jco.2015.33.15_suppl.8035.
- Pietanza M, Spira A, Jotte R, Gadgeel S, Mita A, Hart L, Gluck W, Chiang A, Liu S, Kapoun A, Xu L, Hill D, Dupont J, Spigel D, Zhou L. Final results of phase Ib of tarextumab (TRXT, OMP-59R5, anti-Notch2/3) in combination with etoposide and platinum (EP) in patients (pts) with untreated extensive-stage small-cell lung cancer (ED-SCLC). Journal Of Clinical Oncology 2015, 33: 7508-7508. DOI: 10.1200/jco.2015.33.15_suppl.7508.
- Zhang B, Adelson K, Velji S, Rimar J, Longley P, Keane B, Chiang A, Lilenbaum R. Characterization of aggressive interventions within 30 days of death in lung cancer patients at Smilow Cancer Hospital (SCH). Journal Of Clinical Oncology 2014, 32: 20-20. DOI: 10.1200/jco.2014.32.30_suppl.20.
- Amport S, Shomsky L, Lyons C, Sterling R, Smith M, Beaulieu N, Corjulo D, Adelson K, Chiang A. Development of Smilow's EPIC ambulatory dashboard and the impact on bar code scanning compliance at care centers. Journal Of Clinical Oncology 2014, 32: 166-166. DOI: 10.1200/jco.2014.32.30_suppl.166.
- Pietanza M, Spira A, Jotte R, Gadgeel S, Mita A, Liu S, Gluck W, Kalemkerian G, Chiang A, Hart L, Kapoun A, Xu L, Hill D, Zhou L, Dupont J, Spigel D. 1473P Phase 1B Trial of Anti-Notch 2/3 Antibody Omp-59R5 in Combination with Etoposide and Cisplatin (Ep) in Patients (Pts) with Untreated Extensive-Stage Small-Cell Lung Cancer (Ed-Sclc): the Pinnacle Study. Annals Of Oncology 2014, 25: iv514. DOI: 10.1093/annonc/mdu355.11.
- Chiang A, McNiff K, Kadlubek P, Neuss M, Joseph J. Assessment of quality improvement efforts by ASCO’s Quality Oncology Practice Initiative (QOPI) participants. Journal Of Clinical Oncology 2013, 31: 55-55. DOI: 10.1200/jco.2013.31.31_suppl.55.
- Jagsi R, Chiang A, Medeiros B, Polite B, McNiff K, Zon R, Loehrer P. Qualitative analysis of practicing oncologists’ attitudes and experiences regarding HIT-facilitated collection of patient-reported outcomes. Journal Of Clinical Oncology 2012, 30: 56-56. DOI: 10.1200/jco.2012.30.34_suppl.56.
- Nguyen D, Chiang A, Zhang X, Kim J, Kris M, Ladanyi M, Gerald W, Massagué J. WNT/TCF Signaling through LEF1 and HOXB9 Mediates Lung Adenocarcinoma Metastasis. Journal Of End-to-End-testing 2009, 138: 51-62. DOI: 10.1016/s9999-9994(09)20363-1.
Biography
Anne Chiang, MD, PhD, is a thoracic medical oncologist who cares for patients with lung cancer, including non-small cell lung cancer—the most common kind—and small cell lung cancer. She has concentrated on building a small cell lung cancer program with a comprehensive portfolio of clinical trials testing novel therapeutics for these patients. In addition, she is active as a lung cancer investigator, running a national cooperative group trial for over 800 patients to understand the best frontline therapy for non-small cell lung cancer patients who are PDL1 marker positive.
Researchers are continually investigating new approaches and treatments for all types of cancer, Dr. Chiang says. “I am so optimistic and excited about the impact of clinical research and advances in the field that are helping patients to live longer and better lives, even with a diagnosis of lung cancer,” she says. Her own research background includes translational studies of metastasis, and the development of clinical trials and translational studies to test novel agents and combinations with immune checkpoint inhibitors for both small cell and non-small cell lung tumors. “I am dedicated to quality improvement for patient-centered cancer services and champion the use of patient-reported outcomes,” she says.
Dr. Chiang recently received the American Society of Clinical Oncology 2020 Joseph V. Simone Award and Lecture for excellence in Quality and Safety in the Care of Patients with Cancer. This award was created in honor of Joseph V. Simone, MD, to recognize an extraordinary individual who has made significant contributions to the quality and safety of cancer care. The recipient is an innovator and leader with proven ability to bring projects from conception to broad implementation.
“Listening to and guiding patients when they are diagnosed with cancer is so important,” says Dr. Chiang. “This is a particularly vulnerable time for patients and their families. Good communication can make such a difference on the impact of the diagnosis as well as on the treatment experience.” When seeing a new patient, she often says, “You are in the right place. Our team is here to support you and your family however we can, and to always go the extra mile.”
Titles
- Associate Professor
- Associate Cancer Center Director, Clinical Initiatives
Education & Training
- FellowMemorial Sloan Kettering Cancer Center (2006)
- Senior ResidentNew York Presbyterian Hospital - Columbia Medical Center (2003)
- InternNew York Presbyterian Hospital Columbia Medical Center (2000)
- MDCornell University Medical College (1999)
- PhDHarvard University (1995)
- ABPrinceton University, Molecular Biology (1987)
Languages Spoken
- English
- Deutsch (German)
Additional Information
- CDA Award (2007-2010): ASCO (2007)
- YIA Recipient: ASCO (2005)
- Clinical Scholars Award (2005-2007): Charles Dana Foundation (2005)
- Cancer Chemotherapy Training Program Grantee (2004-2005): National Institute of Health (NIH) (2004)
- Fulbright Fellowship: (1987)
- American Association for Cancer Research (2004 - 2005): Member
- American Society of Hematology (2003 - 2004): Member
- American Society of Clinical Oncology (2003 - Present): Member
- Matteson K, Nassar A, Ellis-Caleo T, Mingo E, Aggarwal V, Sridhar A, Alam S, Crowley F, Aboubakar Nana F, Ahmed M, Grohe C, Zurera Berjaga M, Pinato D, Watson A, Chiang A, Naqash A. Comparison of chemotherapy to chemo-immunotherapy as first-line treatment in patients with advanced large cell neuroendocrine carcinomas (LCNECs) of mixed histology: A multi-institutional international retrospective study. Journal Of Clinical Oncology 2024, 42: 8602-8602. DOI: 10.1200/jco.2024.42.16_suppl.8602.
- Nassar A, Matteson K, Ardeshir F, Gray J, Baena Espinar J, Kwiatkowski D, Aboubakar Nana F, Grohe C, Citarella F, Pancirer D, Cheung J, Watson A, Sridhar A, Crowley F, Kaldas D, Kim C, Sankar K, Awosika N, Naqash A, Chiang A. Exploring systemic treatment approaches for advanced pure large cell neuroendocrine carcinoma (LCNEC): A multicenter retrospective analysis. Journal Of Clinical Oncology 2024, 42: 8106-8106. DOI: 10.1200/jco.2024.42.16_suppl.8106.
- Hummel H, Paz-Ares L, Blackhall F, Chiang A, Dowlati A, Goldman J, Izumi H, Mok T, Sands J, Martinez P, Anderson E, Bharania P, Yu B, Yu Y, Pulla M. 214TiP Tarlatamab after chemoradiotherapy in limited-stage small cell lung cancer (LS-SCLC): DeLLphi-306 (NCT06117774). ESMO Open 2024, 9: 102787. DOI: 10.1016/j.esmoop.2024.102787.
- Jairam V, Soulos P, Madhav K, Gross C, Slotman B, Chiang A, Park H. Differential Effect of Consolidative Thoracic Radiation Therapy in Extensive-Stage Small Cell Lung Cancer Based on Sex. Advances In Radiation Oncology 2023, 9: 101413. PMID: 38778819, PMCID: PMC11110031, DOI: 10.1016/j.adro.2023.101413.
- Gettinger S, Goldberg S, Chiang A, Wilson F, Kim S, Rowen E, Gerrish H, Duffield E, Davies M, Dest V, Jackson R, Pope J, Myint H, Langermann S, Cheng W, Rimm D, Chen L, Herbst R. MA15.07 NC318, an Anti-Siglec-15 Humanized mAb, Alone and in Combination with Pembrolizumab in Immunotherapy Pretreated NSCLC. Journal Of Thoracic Oncology 2023, 18: s155. DOI: 10.1016/j.jtho.2023.09.224.
- Li Y, Yang S, Chiang A, Gross C, Wang S. Using real world practice patterns to identify clinical equipoise in cancer treatment: Advanced non-small cell lung cancer as an exemplar. JCO Oncology Practice 2023, 19: 539-539. DOI: 10.1200/op.2023.19.11_suppl.539.
- Tan J, Yang S, Dinan M, Chiang A, Gross C, Wang S. Mutation-specific costs of advanced non-small cell lung cancer treatment. JCO Oncology Practice 2023, 19: 14-14. DOI: 10.1200/op.2023.19.11_suppl.14.
- Mack P, Redman M, Kozono D, Callis S, Tukachinsky H, Tolba K, Neal J, Waqar S, Dragnev K, Aggarwal C, Hirsch F, Patel J, Herbst R, Chiang A, Reckamp K, Kelly K, Borghaei H, Gray J, Gandara D. The effect of ctDNA tumor fraction (TF) on overall survival and concordance between tissue genomics and ctDNA in Lung-MAP. Journal Of Clinical Oncology 2023, 41: 9035-9035. DOI: 10.1200/jco.2023.41.16_suppl.9035.
- Carbone D, Waqar S, Chaft J, Kris M, Johnson B, Lee J, Wistuba I, Kwiatkowski D, Bunn P, Schulze K, Johnson A, Brandao E, Awad M, Reckamp K, Chiang A, Nicholas A, Rusch V. Abstract CT215: Efficacy and safety of adjuvant (adj) atezolizumab (atezo) from the Phase 2 LCMC3 study. Cancer Research 2023, 83: ct215-ct215. DOI: 10.1158/1538-7445.am2023-ct215.
- Carbone D, Waqar S, Chaft J, Kris M, Johnson B, Lee J, Wistuba I, Kwiatkowski D, Bunn P, Schulze K, Johnson A, Brandao E, Awad M, Reckamp K, Chiang A, Nicholas A, Rusch V. 145MO Updated survival, efficacy and safety of adjuvant (adj) atezolizumab (atezo) after neoadjuvant (neoadj) atezo in the phase II LCMC3 study. Journal Of Thoracic Oncology 2023, 18: s90-s91. DOI: 10.1016/s1556-0864(23)00339-8.
- Power S, Bickel K, Chen R, Chiang A, Garrett-Mayer L, Makhoul I, Mougalian S, Shapiro C, Siegel R, Smith C, Rocque G, Kozlik M, Crist S, Kamal A. Associations of Early Completion of Advance Directives With Key End-of-Life Quality Measures: Analysis of an ASCO Quality Oncology Practice Initiative Patient Cohort. JCO Oncology Practice 2023, 19: e520-e526. PMID: 36669136, DOI: 10.1200/op.22.00464.
- Blinder VS, Garrett-Mayer E, Jacobsen PB, Kozlik MM, Markham MJ, Siegel RD, Kamal AH, Crist STS, Rosenthal J, Chiang AC, _ _. Oral Chemotherapy Metric Performance in Quality Oncology Practice Initiative Practices: Updated Trends and Analysis. Journal Of The National Comprehensive Cancer Network 2022, 20: 1099-1106.e2. PMID: 36240846, DOI: 10.6004/jnccn.2022.7024.
- Chiang A, Kaur M, Assaf Z, Fine A, Zhao Y, Cao Y, Madison R, Oxnard G, Tolba K, Zuniga R, Lakhanpal S, Antic V, Bourla A, Schulze K. EP16.02-002 Circulating Tumor DNA (ctDNA) Changes in Patients With Lung Cancer from a Real-World Prospective Clinico-Genomic (PCG) Study. Journal Of Thoracic Oncology 2022, 17: s571-s572. DOI: 10.1016/j.jtho.2022.07.1033.
- Sands J, Reck M, Navarro A, Chiang A, Lu S, Peled N, Paz-Ares L, Kerr S, Takahashi T, Smolin A, Chen X, Zhao B, El-Osta H, Califano R. KeyVibe-008: Randomized, phase 3 study of first-line vibostolimab plus pembrolizumab plus etoposide/platinum versus atezolizumab plus EP in extensive-stage small cell lung cancer. Journal Of Clinical Oncology 2022, 40: tps8606-tps8606. DOI: 10.1200/jco.2022.40.16_suppl.tps8606.
- Hammon D, Souza E, Chiang A, Shulman L, Kubal T. Plenary Session—The Patient Journey: Access to Cancer Care. Journal Of The National Comprehensive Cancer Network 2022, 20: 1-4. DOI: 10.6004/jnccn.2022.5011.
- Makhoul I, Anders M, Siegel R, Chiang A, Markham MJ, Chen RC, Mougalian S, Arnaoutakis K, Giuliani M, Im A, Kozlik MMP, Crist STS, Garrett-Mayer E, Kamal A. Hematology/Oncology Fellowship Programs' Participation in the Quality Oncology Practice Initiative. JCO Oncology Practice 2022, 18: e1209-e1218. PMID: 35467961, DOI: 10.1200/op.21.00807.
- Siegel RD, Garrett-Mayer E, Lipner RS, Kozlik MMP, Vandergrift JL, Crist STS, Chen RC, Chiang AC, Kamal AH, Force O. Relationship Between Participation in ASCO's Quality Oncology Practice Initiative Program and American Board of Internal Medicine's Maintenance of Certification Program. JCO Oncology Practice 2022, 18: e1350-e1356. PMID: 35363501, DOI: 10.1200/op.21.00777.
- Chen RC, Garrett-Mayer E, Kamal AH, Makhoul I, Kozlik MMP, Crist STS, Chiang AC, Force O. Pre-Treatment Staging Imaging in Rectal Cancer: Results From the Quality Oncology Practice Initiative. JCO Oncology Practice 2022, 18: e1367-e1373. PMID: 35353546, DOI: 10.1200/op.21.00455.
- Sugalski JM, Franco T, Shulman LN, Souza E, Hochberg E, Chiang A, Lawrence S, Krause D, Kubal T. COVID-19 and Cancer Center Operations: Lessons Learned From the NCCN Best Practices Committee. Journal Of The National Comprehensive Cancer Network 2022, 20: 1-4. PMID: 34991065, DOI: 10.6004/jnccn.2021.7102.
- Ganti AKP, Loo BW, Bassetti M, Blakely C, Chiang A, D'Amico TA, D'Avella C, Dowlati A, Downey RJ, Edelman M, Florsheim C, Gold KA, Goldman JW, Grecula JC, Hann C, Iams W, Iyengar P, Kelly K, Khalil M, Koczywas M, Merritt RE, Mohindra N, Molina J, Moran C, Pokharel S, Puri S, Qin A, Rusthoven C, Sands J, Santana-Davila R, Shafique M, Waqar SN, Gregory KM, Hughes M. Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. Journal Of The National Comprehensive Cancer Network : JNCCN 2021, 19: 1441-1464. PMID: 34902832, DOI: 10.6004/jnccn.2021.0058.
- Mbewe A, Pike P, Lewis R, Kortmansky J, Chiang A, Kanowitz J. Implementing the cancer and aging research group (CARG) tool in the ambulatory oncology setting to drive informed treatment selection. Journal Of Clinical Oncology 2021, 39: 209-209. DOI: 10.1200/jco.2020.39.28_suppl.209.
- Newton B, Chiang A. Therapeutic Advances in Small Cell Lung Cancer Management. Current Cancer Research 2021, 175-195. DOI: 10.1007/978-3-030-74028-3_8.
- “The waiting is the worst”: Development of a next day access (NDA) program for patients with cancer.Mougalian S, Shomsky L, Campos M, Chiang A. “The waiting is the worst”: Development of a next day access (NDA) program for patients with cancer. Journal Of Clinical Oncology 2021, 39: 205-205. DOI: 10.1200/jco.2020.39.28_suppl.205.
- Owonikoko T, Boyer M, Johnson M, Govindan R, Rodrigues L, Blackhall F, Boosman R, Champiat S, Hummel H, Lai W, Udagawa H, Chiang A, Dowlati A, Hann C, Salgia R, Vokes E, Minocha M, Sadraei N, Shetty A, Smit M, Zhang Y, Sable B, Pati A, Roy S, Borghaei H. OA11.03 A Phase 1 Study of AMG 757, Half-Life Extended Bispecific T-Cell Engager (BiTE®)Immune Therapy Against DLL3, in SCLC. Journal Of Thoracic Oncology 2021, 16: s126. DOI: 10.1016/j.jtho.2021.01.313.
- Walia G, Lu M, Bourla A, Santos E, Schulze K, Cabili M, Williams E, Mirkovic N, Dicecca R, Lee S, Fang B, Schwartzberg L, Herbst R, Chiang A. P09.55 A Platform to Prospectively Link Real-World Clinico-Genomic, Imaging, and Outcomes Data for Patients With Lung Cancer. Journal Of Thoracic Oncology 2021, 16: s316-s317. DOI: 10.1016/j.jtho.2021.01.483.
- Borghaei H, Boyer M, Johnson M, Govindan R, Rodrigues L, Blackhall F, Boosman R, Champiat S, Hummel H, Lai W, Udagawa H, Chiang A, Dowlati A, Hann C, Salgia R, Vokes E, Minocha M, Hashemi-Sadraei N, Shetty A, Smit M, Yang H, Owonikoko T. 359 AMG 757, a half-life extended bispecific T-cell engager (BiTE®) immune therapy against DLL3 in SCLC: phase 1 interim results. Journal For ImmunoTherapy Of Cancer 2020, 8: a384-a384. DOI: 10.1136/jitc-2020-sitc2020.0359.
- Yang D, Park H, Jairam V, Decker R, Chiang A, Gross C, Yu J. Association Between Prophylactic Cranial Irradiation and Improved Overall Survival in Small Cell Lung Cancer. International Journal Of Radiation Oncology • Biology • Physics 2020, 108: e106. DOI: 10.1016/j.ijrobp.2020.07.1223.
- Owonikoko T, Borghaei H, Champiat S, Paz-Ares L, Govindan R, Boyer M, Johnson M, Udagawa H, Hummel H, Salgia R, Blackhall F, Boosman R, Lai W, Dowlati A, Vokes E, Hann C, Chiang A, Endraca M, Soman N, Smit M. Phase I study of AMG 757, a half-life extended bispecific T-cell engager (HLE BiTE immune therapy) targeting DLL3, in patients with small cell lung cancer (SCLC). Journal Of Clinical Oncology 2020, 38: tps9080-tps9080. DOI: 10.1200/jco.2020.38.15_suppl.tps9080.
- Lu M, Walia G, Schulze K, Doral M, Maund S, Gaffey S, Cabili M, Bourla A, Green R, Santos E, Herbst R, Chiang A, Schwartzberg L. A multi-stakeholder platform to prospectively link longitudinal real-world clinico-genomic, imaging, and outcomes data for patients with metastatic lung cancer. Journal Of Clinical Oncology 2020, 38: tps2087-tps2087. DOI: 10.1200/jco.2020.38.15_suppl.tps2087.
- Yang D, Jairam V, Park H, Decker R, Chiang A, Gross C, Yu J. Use of prophylactic cranial irradiation in patients with extensive-stage small cell lung cancer receiving immunotherapy. Journal Of Clinical Oncology 2020, 38: e19309-e19309. DOI: 10.1200/jco.2020.38.15_suppl.e19309.
- Urick B, Stover A, Deal A, Jansen J, Chiang A, Cleeland C, Zylla D, Basch E. Development and evaluation of patient reported outcomes-based performance measures during chemotherapy. Journal Of Clinical Oncology 2020, 38: e19175-e19175. DOI: 10.1200/jco.2020.38.15_suppl.e19175.
- Stover A, Urick B, Deal A, Jansen J, Henson S, Miller R, Smith T, Scholle S, Chiang A, Cleeland C, Deutsch Y, Zylla D, Pitzen C, Snyder C, McNiff K, Krzyzanowska M, Spears P, Smith M, Geoghegan C, Basch E. ON5 DEVELOPMENT AND TESTING OF PATIENT-REPORTED OUTCOME PERFORMANCE MEASURES (PRO-PMS) FOR COMPARING ONCOLOGY PRACTICES. Value In Health 2019, 22: s413. DOI: 10.1016/j.jval.2019.09.085.
- Keng M, Cunningham G, Gilmore T, Gilligan T, Quinn D, Kaufman L, Bingham J, Guerrier V, Chiang A, Mohamed A, Hagemann J. ASCO Quality Training Program: Five-year review. Journal Of Clinical Oncology 2019, 37: 7-7. DOI: 10.1200/jco.2019.37.27_suppl.7.
- Stover A, Urick B, Deal A, Jansen J, Henson S, Miller R, Smith T, Scholle S, Chiang A, Cleeland C, Deutsch Y, Zylla D, Pitzen C, Snyder C, McNiff K, Krzyzanowska M, Spears P, Smith M, Geoghegan C, Basch E. Development and testing of patient-reported outcome performance measures (PRO-PMs) for oncology practice. Journal Of Clinical Oncology 2019, 37: 173-173. DOI: 10.1200/jco.2019.37.27_suppl.173.
- Dendy Case M, Uhlig J, Blasberg J, Boffa D, Chiang A, Gettinger S, Kim H. Benefit of combining local treatment and systemic therapy for stage IV NSCLC: Results from the National Cancer Database. Journal Of Clinical Oncology 2019, 37: 8545-8545. DOI: 10.1200/jco.2019.37.15_suppl.8545.
- Uhlig J, Dendy M, Goldberg S, Chiang A, Blasberg J, Kim H. 03:00 PM Abstract No. 278 Thermal ablation versus stereotactic radiation therapy for stage 4 lung cancer: contemporary trends and outcomes from the National Cancer Database. Journal Of Vascular And Interventional Radiology 2019, 30: s124-s125. DOI: 10.1016/j.jvir.2018.12.342.
- Kidwai W, Engelking C, Pyle J, Chiang A. Standardizing goals of care (GoC) documentation for new patients with metastatic disease. Journal Of Clinical Oncology 2018, 36: 26-26. DOI: 10.1200/jco.2018.36.34_suppl.26.
- Campbell A, Herbst R, Gettinger S, Goldberg S, Kluger H, Chiang A, Lilenbaum R, Schalper K, Sowell R, Kaech S, Decker R. Final Results of a Phase I Prospective Trial Evaluating the Combination of Stereotactic Body Radiation Therapy (SBRT) with Concurrent Pembrolizumab in Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) or Melanoma. International Journal Of Radiation Oncology • Biology • Physics 2018, 102: s18-s19. DOI: 10.1016/j.ijrobp.2018.06.134.
- Improved acute pain management in oncology patients using early scheduled contact with a pain coach.LaSala J, Chiang A, Severino K. Improved acute pain management in oncology patients using early scheduled contact with a pain coach. Journal Of Clinical Oncology 2018, 36: 293-293. DOI: 10.1200/jco.2018.36.30_suppl.293.
- Chiang A, Adelson K, Kapo J, Severino K, Lilenbaum R. Simple interventions to decrease use of chemotherapy in patients at the end of life. Journal Of Clinical Oncology 2018, 36: 181-181. DOI: 10.1200/jco.2018.36.30_suppl.181.
- Chiang A, Fernandes A, Pavilack M, Wu J, Laliberté F, Duh M, Chehab N, Subramanian J. MA15.11 Real World Biomarker Testing and Treatment Patterns in Patients with Advanced NSCLC Receiving EGFR-TKIs. Journal Of Thoracic Oncology 2018, 13: s410-s411. DOI: 10.1016/j.jtho.2018.08.447.
- Campbell A, Herbst R, Gettinger S, Goldberg S, Kluger H, Chiang A, Lilenbaum R, Schalper K, Sowell R, Kaech S, Decker R. Final results of a phase I prospective trial evaluating the combination of stereotactic body radiotherapy (SBRT) with concurrent pembrolizumab in patients with metastatic non-small cell lung cancer (NSCLC) or melanoma. Journal Of Clinical Oncology 2018, 36: 9099-9099. DOI: 10.1200/jco.2018.36.15_suppl.9099.
- Goldberg S, Gettinger S, Mahajan A, Herbst R, Chiang A, Lilenbaum R, Jilaveanu L, Rowen E, Gerrish H, Komlo A, Wei W, Chiang V, Kluger H. Durability of brain metastasis response and overall survival in patients with non-small cell lung cancer (NSCLC) treated with pembrolizumab. Journal Of Clinical Oncology 2018, 36: 2009-2009. DOI: 10.1200/jco.2018.36.15_suppl.2009.
- Talsania A, Chiang A. Chapter 7 A Practical Approach to Management of Small Cell Lung Cancer. 2018, 117-129. DOI: 10.1016/b978-0-323-48565-4.00007-2.
- Daniel D, Rudin C, Hart L, Spigel D, Edelman M, Goldschmidt J, Bordoni R, Glisson B, Burns T, Dowlati A, Dy G, Beck T, Jotte R, Liu S, Kapoun A, Faoro L, Chiang A. 1530PD Results of a randomized, placebo-controlled, phase 2 study of tarextumab (TRXT, anti-Notch2/3) in combination with etoposide and platinum (EP) in patients (pts) with untreated extensive-stage small-cell lung cancer (ED-SCLC). Annals Of Oncology 2017, 28: v540. DOI: 10.1093/annonc/mdx386.004.
- Zhang C, Graf R, Jendrisak A, Anderson A, Ontiveros P, Orr S, Chiang A, Spigel D, Rudin C, Holmgren E, Dupont J, Argast G, Faoro L, Zhou L, Lewicki J, Kapoun A. Abstract 1727: Circulating Tumor Cells (CTCs) in patients with extensive stage small cell lung cancer and their association with clinical outcome. Cancer Research 2017, 77: 1727-1727. DOI: 10.1158/1538-7445.am2017-1727.
- O'Connor J, Seidl-Rathkopf K, You P, Nussbaum N, Torres A, Fessele K, Darius K, Adelson K, Yin E, Presley C, Chiang A, Ross J, Abernethy A, Gross C. Adoption of immunotherapy into real-world practice: Insights from the use of checkpoint inhibitors. Journal Of Clinical Oncology 2017, 35: e14583-e14583. DOI: 10.1200/jco.2017.35.15_suppl.e14583.
- Presley C, Soulos P, Chiang A, Longtine J, Adelson K, Herbst R, Nussbaum N, Sorg R, Abernethy A, Agarwala V, Gross C. Disparities in next generation sequencing in a population-based community cohort of patients with advanced non-small cell lung cancer. Journal Of Clinical Oncology 2017, 35: 6563-6563. DOI: 10.1200/jco.2017.35.15_suppl.6563.
- O'Connor J, Seidl-Rathkopf K, Torres A, You P, Nussbaum N, Fessele K, Darius K, Adelson K, Yin E, Presley C, Chiang A, Ross J, Abernethy A, Gross C. Racial disparities in the use of programmed death-1 checkpoint inhibitors. Journal Of Clinical Oncology 2017, 35: 3068-3068. DOI: 10.1200/jco.2017.35.15_suppl.3068.
- Adelson K, Stutsky M, Fradkin M, Harrison M, Abdelghany O, Morrow B, Smith M, Havriliak R, Kregling S, Lyons C, Chiang A, Cohen H. Should Cancer Centers start their own specialty pharmacy? Quality and economic data from the oral chemotherapy program at Smilow Cancer Hospital and Yale New Haven Health System. Journal Of Clinical Oncology 2017, 35: 108-108. DOI: 10.1200/jco.2017.35.8_suppl.108.
- Chiang A, Reeder-Hayes K, McNiff K, Evans T, Lennes I, Eaton E, Kamal A. Challenges, barriers, and keys to success for sustainable quality improvement in oncology: A focus group of oncology quality leaders. Journal Of Clinical Oncology 2017, 35: 78-78. DOI: 10.1200/jco.2017.35.8_suppl.78.
- Chiang A, Barysauskas C, Conti-Kalchik T, Gilmore T, Hendricks C, Neuss M, Jacobson J. Comparison of initial and recertification QOPI scores: Maintaining compliance through direct surveyor and practice interaction. Journal Of Clinical Oncology 2017, 35: 246-246. DOI: 10.1200/jco.2017.35.8_suppl.246.
- Barbarotta L, Jauk M, Chiang A, Sanft T. Hard-wiring survivorship care plan delivery. Journal Of Clinical Oncology 2017, 35: 113-113. DOI: 10.1200/jco.2017.35.8_suppl.113.
- Lu C, Morgensztern D, Chiang A, Onn A, Sepesi B, Vaporciyan A, Chang J, Komaki R, Wistuba I, Herbst R. Cancer of the Lung. 2017, 1-30. DOI: 10.1002/9781119000822.hfcm085.
- Chiang A, Ellis P, Zon R. Perspectives on the Use of Clinical Pathways in Oncology Care. American Society Of Clinical Oncology Educational Book 2017, 37: 155-159. DOI: 10.14694/edbk_175533.
- Decker R, Goldberg S, Nath S, Husain Z, Lilenbaum R, Schalper K, Chiang A, Altan M, Zelterman D, Kaech S, Herbst R, Gettinger S. P3.02c-048 A Phase I/II Trial Evaluating the Combination of Stereotactic Body Radiotherapy and Pembrolizumab in Metastatic NSCLC Topic: IT. Journal Of Thoracic Oncology 2017, 12: s1303-s1304. DOI: 10.1016/j.jtho.2016.11.1843.
- Sequist L, Chiang A, Gilbert J, Gordon M, Conkling P, Thompson D, Marcoux J, Antonia S, Liu B, Shames D, Lopez-Chavez A, O'Hear C, Fasso M, Gettinger S. 1425PD Clinical activity, safety and predictive biomarkers results from a phase Ia atezolizumab (atezo) trial in extensive-stage small cell lung cancer (ES-SCLC). Annals Of Oncology 2016, 27: vi493. DOI: 10.1093/annonc/mdw389.03.
- Badin F, Chiang A, Fisher W, Orlov S, Harper H, Eskander E, Harb W, Kio E, Gopalan P, Haggstrom D, Burdaeva O, Zahlten-Kumeli A, Aggarwal S, Obreja M, Gorbunova V. Carfilzomib (CFZ), carboplatin and etoposide for previously untreated extensive-stage small cell lung cancer (ES-SCLC): Phase 1b results from a phase 1b/2 study. Journal Of Clinical Oncology 2016, 34: e20092-e20092. DOI: 10.1200/jco.2016.34.15_suppl.e20092.
- Xia B, Wurtz A, Gettinger S, Herbst R, Chiang A, Wan M, Sklar J, Neumeister V, Politi K, Goldberg S. HER2 amplification in EGFR mutant NSCLC after acquired resistance (AR) to EGFR-directed therapies. Journal Of Clinical Oncology 2016, 34: 9049-9049. DOI: 10.1200/jco.2016.34.15_suppl.9049.
- Schalper K, Carvajal-Hausdorf D, McLaughlin J, Altan M, Chiang A, Velcheti V, Kaftan E, Zhang J, Lu L, Rimm D, Han B, Lu H, Zhao H, Herbst R. Objective measurement and significance of PD-L1, B7-H3, B7-H4 and TILs in small cell lung cancer (SCLC). Journal Of Clinical Oncology 2016, 34: 8566-8566. DOI: 10.1200/jco.2016.34.15_suppl.8566.
- Chiang A, Rudin C, Spira A, Jotte R, Gadgeel S, Mita A, Hart L, Gluck W, Liu S, Kapoun A, Xu L, Hill D, Zhou L, Dupont J, Spigel D. Updated results of phase 1b study of tarextumab (TRXT, anti-Notch2/3) in combination with etoposide and platinum (EP) in patients (pts) with untreated extensive-stage small-cell lung cancer (ED-SCLC). Journal Of Clinical Oncology 2016, 34: 8564-8564. DOI: 10.1200/jco.2016.34.15_suppl.8564.
- Gettinger S, Zhang X, Homer R, Possick J, Wurtz A, Goldberg S, Chiang A, Herbst R, Rubinowitz A. Pneumonitis in non-small cell lung cancer (NSCLC) patients treated with programmed death 1 (PD1) axis inhibitors. Journal Of Clinical Oncology 2016, 34: 9030-9030. DOI: 10.1200/jco.2016.34.15_suppl.9030.
- Stover A, Chiang A, Basch E. ASCO PRO workgroup update: Patient-reported outcome measures as a quality indicator. Journal Of Clinical Oncology 2016, 34: 276-276. DOI: 10.1200/jco.2016.34.7_suppl.276.
- Amport S, Adelson K, Fradkin M, Havriliak R, Harrison M, Abdelghany O, Kregling S, Wright J, Morrow B, Sterling R, Smith M, Esposito F, Stutsky M, Miller L, Lilenbaum R, Lyons C, Chiang A, Cohen H. Multidisciplinary process improvement to optimize oral chemotherapy safety. Journal Of Clinical Oncology 2016, 34: 134-134. DOI: 10.1200/jco.2016.34.7_suppl.134.
- Chiang A. Why the Quality Oncology Practice Initiative Matters: It’s Not Just About Cost. American Society Of Clinical Oncology Educational Book 2016, 36: e102-e107. DOI: 10.14694/edbk_160113.
- Goldberg S, Gettinger S, Mahajan A, Herbst R, Chiang A, Tsiouris A, Vortmeyer A, Jilaveanu L, Speaker S, Madura M, Rowen E, Gerrish H, Knapp-Perry E, Yao X, Chiang V, Kluger H. Activity and safety of pembrolizumab in patients with metastatic non-small cell lung cancer with untreated brain metastases. Journal Of Clinical Oncology 2015, 33: 8035-8035. DOI: 10.1200/jco.2015.33.15_suppl.8035.
- Pietanza M, Spira A, Jotte R, Gadgeel S, Mita A, Hart L, Gluck W, Chiang A, Liu S, Kapoun A, Xu L, Hill D, Dupont J, Spigel D, Zhou L. Final results of phase Ib of tarextumab (TRXT, OMP-59R5, anti-Notch2/3) in combination with etoposide and platinum (EP) in patients (pts) with untreated extensive-stage small-cell lung cancer (ED-SCLC). Journal Of Clinical Oncology 2015, 33: 7508-7508. DOI: 10.1200/jco.2015.33.15_suppl.7508.
- Zhang B, Adelson K, Velji S, Rimar J, Longley P, Keane B, Chiang A, Lilenbaum R. Characterization of aggressive interventions within 30 days of death in lung cancer patients at Smilow Cancer Hospital (SCH). Journal Of Clinical Oncology 2014, 32: 20-20. DOI: 10.1200/jco.2014.32.30_suppl.20.
- Amport S, Shomsky L, Lyons C, Sterling R, Smith M, Beaulieu N, Corjulo D, Adelson K, Chiang A. Development of Smilow's EPIC ambulatory dashboard and the impact on bar code scanning compliance at care centers. Journal Of Clinical Oncology 2014, 32: 166-166. DOI: 10.1200/jco.2014.32.30_suppl.166.
- Pietanza M, Spira A, Jotte R, Gadgeel S, Mita A, Liu S, Gluck W, Kalemkerian G, Chiang A, Hart L, Kapoun A, Xu L, Hill D, Zhou L, Dupont J, Spigel D. 1473P Phase 1B Trial of Anti-Notch 2/3 Antibody Omp-59R5 in Combination with Etoposide and Cisplatin (Ep) in Patients (Pts) with Untreated Extensive-Stage Small-Cell Lung Cancer (Ed-Sclc): the Pinnacle Study. Annals Of Oncology 2014, 25: iv514. DOI: 10.1093/annonc/mdu355.11.
- Chiang A, McNiff K, Kadlubek P, Neuss M, Joseph J. Assessment of quality improvement efforts by ASCO’s Quality Oncology Practice Initiative (QOPI) participants. Journal Of Clinical Oncology 2013, 31: 55-55. DOI: 10.1200/jco.2013.31.31_suppl.55.
- Jagsi R, Chiang A, Medeiros B, Polite B, McNiff K, Zon R, Loehrer P. Qualitative analysis of practicing oncologists’ attitudes and experiences regarding HIT-facilitated collection of patient-reported outcomes. Journal Of Clinical Oncology 2012, 30: 56-56. DOI: 10.1200/jco.2012.30.34_suppl.56.
- Nguyen D, Chiang A, Zhang X, Kim J, Kris M, Ladanyi M, Gerald W, Massagué J. WNT/TCF Signaling through LEF1 and HOXB9 Mediates Lung Adenocarcinoma Metastasis. Journal Of End-to-End-testing 2009, 138: 51-62. DOI: 10.1016/s9999-9994(09)20363-1.